Ashwagandha Supplements UK — What the Evidence Says

What is Ashwagandha?

Ashwagandha is a small evergreen shrub native to India, North Africa, and parts of the Mediterranean. Its scientific name is Withania somnifera, and it belongs to the Solanaceae family. The plant's root is the part most commonly used in supplements, though leaf extracts are also available.

In Ayurvedic medicine, ashwagandha has been used for several thousand years. It is classified as a rasayana, a category of herbs used in traditional Indian medicine to support general wellbeing and resilience. The name itself comes from Sanskrit, roughly translating to "smell of horse," a reference to both the root's distinctive aroma and its traditional associations with strength.

Modern supplement products typically use a dried, powdered root extract, often standardised to a specific percentage of withanolides. The most widely researched commercial extracts are KSM-66 and Sensoril, both of which use proprietary standardisation methods. Understanding which extract a product contains, and at what dose, is central to how Cogniscore evaluates any product listing ashwagandha on its label.

Key Active Compounds

The primary bioactive compounds in ashwagandha are the withanolides, a group of naturally occurring steroidal lactones. The two most studied are withaferin A and withanolide D. Clinical research on ashwagandha has typically used extracts standardised to a defined withanolide percentage, which is why this figure matters when assessing a supplement label.

The root also contains alkaloids, including somnine and somniferine, as well as sitoindosides and glycowithanolides. These compounds appear alongside withanolides in full-spectrum root extracts and are present in varying concentrations depending on the extraction method used.

Cogniscore looks for withanolide percentage disclosure on product labels and certificates of analysis (COAs) because it is the figure most commonly reported in clinical trials. Without it, there is no way to compare a product's composition against the extracts used in research. A product that lists only "ashwagandha root extract" without a standardisation figure provides limited information for scoring purposes. Products that disclose the extract type (such as KSM-66 or Sensoril), the withanolide percentage, and a third-party COA score considerably higher on the Cogniscore disclosure rubric.

Benefit Areas Studied in Research

Stress. Ashwagandha has been studied in human trials for its relationship with perceived stress. Several randomised controlled trials (RCTs) have used validated stress scales, such as the Perceived Stress Scale, to examine participant responses over periods of eight to twelve weeks. These studies have used standardised root extracts at doses ranging from 300mg to 600mg per day.

Cortisol levels. A number of clinical trials have used serum cortisol measurement as an outcome when examining ashwagandha. Researchers have looked at whether supplementation with standardised root extract is associated with changes in circulating cortisol in adults reporting stress. These trials have generally been human RCTs of eight to twelve weeks' duration.

Sleep quality. Research has examined ashwagandha in the context of sleep, with some studies using objective sleep measures and self-reported sleep quality questionnaires. Trials examining sleep have typically used doses of 300mg to 600mg of standardised root extract and have included both healthy adults and those reporting sleep difficulties.

Cognitive function. Clinical research has looked at ashwagandha in relation to cognitive outcomes including memory and attention. Some human trials have used neuropsychological testing batteries to measure cognitive performance in participants taking standardised extracts, generally over eight to twelve weeks.

Physical endurance. Some studies have examined ashwagandha in the context of physical performance, including measures of cardiorespiratory endurance and muscle recovery. These trials have typically involved healthy adults engaged in resistance or aerobic training and have used standardised root extracts at doses of 300mg to 600mg per day.

The Science and Research

The evidence base for ashwagandha is broader than for many botanical supplements. The most cited trials are human RCTs, though the field includes exploratory and observational studies as well. Sample sizes across the literature tend to be modest, and some trials have industry involvement, which is worth noting when interpreting findings.

In a 2012 RCT, Chandrasekhar and colleagues examined stress and cortisol outcomes using a high-concentration full-spectrum ashwagandha root extract (KSM-66) at 300mg twice daily (600mg total per day) over 60 days. The study was double-blind and placebo-controlled, with 64 adult participants reporting chronic stress. The trial measured serum cortisol and scores on the Perceived Stress Scale. It was published in the Indian Journal of Psychological Medicine. Limitations include the relatively small sample size and the fact that the extract studied is a proprietary formulation, which limits direct comparison with non-standardised products.

Also in 2012, Raut and colleagues published an exploratory study examining tolerability, safety, and activity of ashwagandha root extract in 18 healthy adult volunteers over 30 days. Participants received a dose of 750mg to 1,250mg per day in a dose-escalating design. This was not a placebo-controlled trial, and the small sample means the findings carry limited statistical weight. The study was published in Ayu and is more useful as a safety and tolerability reference than an efficacy source.

Pratte and colleagues (2014) published a systematic review of human trial results for ashwagandha in the context of anxiety, covering trials published up to that point. The review appeared in the Journal of Alternative and Complementary Medicine and examined results across multiple study designs. Systematic reviews are useful for summarising a body of evidence, but their conclusions are only as strong as the underlying trials. Several included studies were small, and the authors noted significant variation in extract types, doses, and outcome measures across trials.

Across the literature, the doses studied most consistently in human RCTs fall between 300mg and 600mg per day of standardised root extract. Studies using doses outside this range, or using non-standardised powders, are harder to compare directly. The distinction between KSM-66 (a root-only extract) and Sensoril (which uses both root and leaf) is also relevant, as the two extracts have different withanolide profiles and have been studied in separate trials.

How Cogniscore Evaluates Ashwagandha

When Cogniscore scores a product containing ashwagandha, the first check is dose per serving. The dose range most commonly used in human RCTs is 300mg to 600mg of standardised root extract per day. Products disclosing a dose within this range score higher than those using doses below 300mg or those that do not disclose a dose at all. Products containing ashwagandha within a proprietary blend, where the individual ingredient dose is not stated, receive a lower score on this criterion regardless of the blend's total weight.

Extract type and standardisation also affect the score. A product that names the extract (KSM-66 or Sensoril, for example) and discloses a withanolide percentage scores higher than one listing only "ashwagandha root extract" with no further detail. Third-party testing, evidenced by a publicly available COA from an accredited laboratory, adds further to the disclosure score. The COA allows independent confirmation of withanolide content and screens for contaminants. See the full Cogniscore methodology for a complete breakdown of how each criterion is weighted.

Top Rated Products Containing Ashwagandha

Ranked by Cogniscore — highest disclosure scores first. Scores reflect what brands publicly disclose, not product quality or efficacy.

No scored products containing Ashwagandha are currently listed. Check back as the database grows.

Frequently Asked Questions

This page was generated with AI assistance based on publicly available data. Report an error: corrections@cogniscore.co.uk